Payment overview · 2025
General Payments
$559.87
25 reported records · 9 companies
Healthcare provider profile · identity verified
Eric Reynolds, NP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · VERNAL, UT · NPI 1710311279
Verified facts
What the public records show
CMS Open Payments records show Eric Reynolds, NP-C received $559.87 in general payments during 2025 across 25 reported records.
AstraZeneca Pharmaceuticals LP accounted for 42.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BYETTA as an associated drug or biological on 60 records involving 49 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Byetta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $239.45 | 42.8% | 12 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $108.60 | 19.4% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $45.65 | 8.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $41.27 | 7.4% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $31.23 | 5.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $26.12 | 4.7% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.41 | 4.2% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $23.40 | 4.2% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $20.74 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $559.87 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $108.60 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $103.38 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $89.62 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $46.45 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $45.65 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $41.27 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $26.12 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $23.41 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $23.40 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $20.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 144 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BYETTA open payments reported associated product |
CMS Open Payments — General Payments 60 supporting records · 49 recipient NPIs · example record 1206154618 |
Byetta · 2024 Exact normalized brand match · 1 Part D row |
25 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
144 | 49 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
82 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Farxiga | Dapagliflozin Propanediol | 144 | 49 |
| Levothyroxine Sodium | Levothyroxine Sodium | 131 | 40 |
| Atorvastatin Calcium | Atorvastatin Calcium | 114 | 41 |
| Omeprazole | Omeprazole | 99 | 32 |
| Lisinopril | Lisinopril | 98 | 34 |
| Gabapentin | Gabapentin | 96 | 26 |
| Ozempic | Semaglutide | 82 | 12 |
| Januvia | Sitagliptin Phosphate | 80 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 74 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 69 | 20 |
| Eliquis | Apixaban | 66 | 22 |
| Amlodipine Besylate | Amlodipine Besylate | 64 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 64 | 21 |
| Jardiance | Empagliflozin | 59 | 22 |
| Losartan Potassium | Losartan Potassium | 57 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 53 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | suppressed |
| Ibuprofen | Ibuprofen | 44 | suppressed |
| Xarelto | Rivaroxaban | 42 | 16 |
| Potassium Chloride | Potassium Chloride | 40 | 15 |
| Enbrel Sureclick | Etanercept | 39 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 39 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | 13 |
| Metformin Hcl | Metformin Hcl | 37 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 37 | suppressed |
| Carvedilol | Carvedilol | 34 | 15 |
| Furosemide | Furosemide | 34 | 16 |
| Levemir Flexpen | Insulin Detemir | 34 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 34 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 33 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 32 | suppressed |
| Prednisone | Prednisone | 31 | 12 |
| Simvastatin | Simvastatin | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 29 | 11 |
| Sertraline Hcl | Sertraline Hcl | 29 | suppressed |
| Lorazepam | Lorazepam | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Byetta | Exenatide | 25 | 11 |
| Glipizide Er | Glipizide | 25 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 25 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 25 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Allopurinol | Allopurinol | 24 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Meloxicam | Meloxicam | 23 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Famotidine | Famotidine | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $559.87 · 25 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, FARXIGA, Korlym, Ohtuvayre, REXULTI, Sunosi, VRAYLAR, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error